TXT							Pathology				Gender				Smoking Status
		IPD			CR, PR		SD		PD		NE	Adeno		Other		♂		♀		Smoker		Non-Smoker													BAC Component
	Sample Origin	T/ N/ T+N	Mut	T	Mut	WT	Mut	WT	Mut	WT		T	Mut	T	Mut	T	Mut	T	Mut	T	Mut	T	Mut	≥2 Mut	Exons Screened and or Genotyping	Technique(s)	DNA/RNA	Biological Sample	Confirmed Somatic	Response criteria	TKI	Treatment Status	Author confirmed	Author Contacted	Mut	WT	Gene Amp	k-RAS
Chou TY, et al.  Clin Cancer Res 2005; 11: 3750-3757.	Taiwan	1t	33	54	17	8	12	4	4	5	8	43	29	11	4	29	15	25	18	18	8	36	25	2	18-21	Seq	DNA	PET	N	R	G	P
Mu XL, et al. Clin Cancer Res 2005; 11: 4289-4294.	China	5t	10	22	7	0	3	4	0	8	0	16	9	6	1	10	3	12	7	^	^	^	^	0	18-21	Seq	DNA	PET	N	R	G	P
Mu XL, et al. Clin Cancer Res 2005; 11: 4289-4294.	China	5n	18	54	^	^	^	^	^	^	^	35	17	19	1	31	10	23	8	^	^	^	^	1	18-21	Seq	DNA	PET	N	^	^	^
Kimura H, et al. Cancer Sci 2006; 97: 642-648.	Japan	13t	4	7	4	0	0	1	0	2	0	7	4	0	0	4	3	3	1	3	2	4	2	0	18-21	Seq, Scorpion ARMS del E746-A750 and L858R	DNA	Pleural effusion	N	R	G	P
Kimura H, et al. Cancer Sci 2006; 97: 642-648.	Japan	13n	4	17	^	^	^	^	^	^	^	16	4	1	0	9	0	8	4	11	1	6	3	0	18-21	Seq, Scorpion ARMS del E746-A750 and L858R	DNA	Pleural effusion	N	^	^	^
Kimura H, et al. Br J Cancer 2006; 95: 1390-1395	Japan	139t	8	27	7	0	1	6	0	13	0	26	8	1	0	10	3	17	5	13	3	14	5	0	18-21	Seq	DNA	Pleural effusion	N	R	G	P
Kimura H, et al. Br J Cancer 2006; 95: 1390-1396	Japan	139n	3	16	^	^	^	^	^	^	^	13	3	3	0	12	1	4	2	12	1	4	2	0	18-21	Seq	DNA	Pleural effusion	N	^	^	^
Han SW, et al. Lung Cancer 2006; 54: 201-207.	Korea	39t	23	120	13	12	^	^	^	^	95	83	10	37	13	70	9	50	14	67	15	53	8	1	18,19,21	Seq	DNA	PET	N	WHO	G	P
Han SW, et al. J Clin Oncol 2005; 23: 2493-2501	Korea	3t	17	90	11	10	4	23	2	40	0	65	14	25	3	54	5	36	12	47	6	43	11	1	18,19,21,23	Seq	DNA	PET	N	WHO	G	P
Han SW, et al. Clin Cancer Res 2006; 12: 2538-2544.	Korea	4t	15	69	8	8	0	0	7	46	0	52	^	17	^	39	^	30	^	34	^	35	^	2	18-21	Seq	DNA	PET	N	WHO	G	P
Lee KH, et al. Jpn J Clin Oncol 2006; 36: 344-350.	Korea	107t	17	90	^	^	^	^	^	^	4	^	^	^	^	^	^	^	^	^	^	^	^	0	18,19,21	Seq	DNA	PET	N	WHO	G	P
Han SW, et al. Pharmacogenetics and Genomics 2007; 17: 313-319.	Korea	391t	20	86	9	7	^	^	^	^	70	60	^	26	^	49	^	37	^	48	^	38	^	3	18-21,23	Seq	DNA	PET	N	WHO	G	P
Mitsudomi T, et al. J Clin Oncol 2005; 23: 2513-2520.	Japan	41t	33	59	24	2	0	4	5	15	9	50	32	9	1	32	14	27	19	31	13	28	20	2	18-21	Seq	RNA	FF	N	R	G	P
Shimato S, et al. Neuro-Oncology 2006; 8: 137-144.	Japan	199t	5	8	^	^	^	^	^	^	8	6	5	2	0	6	4	2	1	^	^	^	^	0	18-21	Seq	RNA	FF	N	R	G	P
Fujiwara Y, et al. Lung Cancer 2006; 52: 99-103.	Japan	43t	11	26	^	^	^	^	^	^	26	22	11	4	0	15	4	11	7	15	2	11	9	0	18-21	Seq	DNA	PET/FF	N	WHO	G	P
Tokumo M, et al. Clin Cancer Res 2005; 11: 1167-1173.	Japan	46t	9	21	8	2	1	7	0	3	0	15	8	6	1	13	4	8	5	13	2	8	7	0	18-24	Seq	DNA	PET	N	ECOG	G	P
Tokumo M, et al. Clin Cancer Res 2005; 11: 1167-1173.	Japan	46n	30	99	^	^	^	^	^	^	^	67	29	32	1	70	13	29	16	71	11	28	18	0	18-24	Seq	DNA	PET	N	^	^	^
Huang SF, et al. Clin Cancer Res 2004; 10: 8195-8203.	Taiwan	52t	8	16	6	0	1	2	1	6	0	15	8	1	0	4	2	12	6	4	1	12	7	2	18-21	Seq	DNA	PET	N	R	G	P
Huang SF, et al. Clin Cancer Res 2004; 10: 8195-8203.	Taiwan	52n	39	101	^	^	^	^	^	^	^	69	38	32	1	56	18	45	21	28	^	65	^	7	18-21	Seq	DNA	FF	N	^	^	^
Hsieh MH, et al. Lung Cancer 2006; 53: 311-322.	Taiwan	93t	32	65	20	2	2	5	8	26	2	52	30	13	2	28	13	37	19	22	7	43	25	7	18-21	Seq, TaqMan (L858R, L861Q, delE756-A750)	DNA	PET/FF	N	R	G	P
Bell DW, et al. J Clin Oncol 2005; 23: 8081-8092.	Asian, Caucasian	54n+t	46	391	^	^	^	^	^	^	^	213	37	178	9	267	23	124	23	284	22	55	14	0	18-21	Seq	DNA	PET	N	^	^	^
Tomizawa Y, et al. Clin Cancer Res 2005; 11: 6816-6822.	Japan	59t	10	20	10	4	^	^	^	^	6	18	10	2	0	9	4	11	6	9	4	11	6	0	18-21	Seq, SSCP	DNA	PET	N	^	G	N
Tomizawa Y, et al. Clin Cancer Res 2005; 11: 6816-6822.	Japan	59n	19	100	^	^	^	^	^	^	^	26	19	45	0	68	5	32	14	62	5	32	14	0	18-21	Seq, SSCP	DNA	FF	N	^	^	^
Shih JY, et al. Int J Cancer 2006; 118: 963-969.	Taiwan	62t	29	62	20	3	8	12	1	18	0	57	28	5	1	24	6	38	23	21	6	41	23	4	18-21	Seq	DNA	PET	Y	R	G	P
Uramoto H, et al. Lung Cancer 2006; 51: 71-77.	Japan	69t	9	20	7	0	2	5	0	6	0	17	9	3	0	11	5	9	4	12	4	8	5	0	18-23	Seq	DNA	PET/FF	N	R	G	P
Takano T, et al. J Clin Oncol 2005; 23: 6829-6837.	Japan	78t	39	66	32	3	4	5	3	19	0	62	38	4	1	40	21	26	18	35	18	31	21	4	18-24	Seq	DNA	PET	Y	R	G	P
Nomoto K, et al. Am J Clin Pathol 2006; 126: 608-615.	Japan	145t	14	28	^	^	^	^	^	^	28	26	13	2	1	^	^	^	^	^	^	^	^	0	18-24	HRMA	DNA	Cytology	N	R	G	P
Oshita F, et al. Br J Cancer 2006; 95: 1070-1075.	Japan	81t	11	25	10	2	1	8	0	4	0	22	10	3	1	8	1	17	10	11	2	14	9	2	19,21	LH-MSH	DNA	Cytology	N	^	G	P
Taja-Chayeb L, et al. Lung Cancer 2005; 50: 259-263.	Mexico	83t	0	1	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	1	0	0	18-24	Seq	DNA	PET	N	^	G	P
van Zandwijk N, et al. Ann Oncol 2007; 18: 99-103.	Japan	87t	13	41	11	^	1	^	0	^	1	^	12	^	1	^	6	^	7	^	3	^	10	1	18-21	Seq	DNA	PET	N	R	G/E	P
van Zandwijk N, et al. Ann Oncol 2007; 18: 99-103.	Netherlands	87t	3	15	3	0	0	2	0	10	0	10	3	5	0	7	1	8	2	13	2	2	1	0	18-21	Seq	DNA	PET	N	R	G	P
Janne PA, et al. Clin Cancer Res 2006; 12: 751-758.	USA	108t	11	26	11	1	0	6	0	8	0	17	7	1	0	5	0	19	11	^	^	^	^	1	18-21	Surveyor	DNA	P	N	WHO	G	P
Janne PA, et al. Clin Cancer Res 2006; 12: 751-758.	USA	108n	13	61	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	1	18-21	Surveyor	DNA	FF	N	^	^	^
Paez JG, et al. Science 2004; 304: 1497-1500.	Japan & USA	89t	5	9	5	0	0	0	0	4	0	8	5	1	0	3	2	7	3	^	^	^	^	0	Gene	Seq	DNA	PET	Y	R	G	P
Paez JG, et al. Science 2004; 304: 1497-1500.	Japan & USA	89n	16	119	^	^	^	^	^	^	^	70	15	49	1	74	6	45	10	^	^	^	^	0	Gene	Seq	DNA	PET	N	^	^	^
Lynch TJ, et al. NEJM 2004; 350: 2129-2139.	USA	90t	8	9	7	1	1	0	0	0	0	9	8	0	0	3	3	6	5	3	3	6	5	0	Gene	Seq	DNA	PET	Y	R	G	P
Lynch TJ, et al. NEJM 2004; 350: 2129-2139.	USA	90n	2	25	^	^	^	^	^	^	^	22	2	3	0	^	^	^	^	^	^	^	^	0	Gene	Seq	DNA	PET	N	^	^	^
Kwak EL, et al. PNAS 2005; 102: 7665-7670.	USA	40t	2	2	0	0	0	0	2	0	0	2	2	0	0	^	^	^	^	^	^	^	^	2	Gene	Seq	DNA	PET	N	R	G	^
Cappuzzo F, et al. JNCI 2005; 97: 643-655.	Italy & USA	97t	15	89	8	4	1	20	6	50	0	58	12	31	3	58	7	31	8	76	9	13	6	0	18,19,21	Seq	RNA	PET	N	R	G	P
Dziadziuszko R, et al. Clin Cancer Res 2006; 12: 3078-3084.	Italy & USA	109t	13	82	7	^	^	^	^	^	82	53	^	29	^	56	^	26	^	69	^	13	^	0	18,19,21	Seq	RNA	PET	N	R	G	P
Hirsch FR, et al. Ann Oncol 2007; 18: 752-760.	Italy & USA	193t	43	157	16	8	6	34	19	73	0	123	37	32	6	91	18	66	25	126	30	31	13	1	18,19,21	Seq	DNA	PET	N	R	G	P
Endo K, et al. Lung Cancer 2005; 50: 375-384.	Japan	82t	9	27	6	3	6	0	0	0	13	^	^	^	^	^	^	^	^	^	^	^	^	1	18-21	Seq, TaqMan (13)	DNA	PET/FF	N	^	G	^
Endo K, et al. Lung Cancer 2005; 50: 375-384.	Japan	82n	18	67	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	G719S, delEx19, L858R	LightCycler	DNA	PET/FF	N	^	^	^
Endo K, et al. Lung Cancer 2005; 50: 375-384.	Japan	82n	46	182	^	^	^	^	^	^	^	97	45	85	1	127	17	55	29	113	12	46	27	0	18,19,21	TaqMan (13)	DNA	PET/FF	Y	^	^	^
Sasaki H, et al. Clin Cancer Res 2005; 11: 2924-2929.	Japan	72t	6	14	^	^	^	^	^	^	14	14	6	0	0	6	3	8	3	5	2	9	4	0	G719S, delEx19, L858R	LightCycler	DNA	FF	Y	^	G	^
Sasaki H, et al. Clin Cancer Res 2005; 11: 2924-2929.	Japan	72n	16	102	^	^	^	^	^	^	^	49	13	48	3	81	5	21	11	^	5	^	11	0	G719S, delEx19, L858R	LightCycler	DNA	FF	Y	^	^	^
Sasaki H, et al. Int J Cancer 2006; 118: 180-184.	Japan	35n	35	95	^	^	^	^	^	^	^	39	32	24	3	65	13	30	22	59	10	36	25	1	18-21	Seq	RNA	FF	Y	^	^	^
Sasaki H, et al. Oncology Reports 2007; 17: 319-323.	Japan	361n	60	252	^	^	^	^	^	^	^	139	56	113	4	188	21	64	39	182	20	70	40	0	18-21	Seq, TaqMan (13), LightCycler	RNA	FF	N	^	^	^
Sasaki H, et al. Oncology Reports 2007; 17: 319-323.	Japan	361t	9	14	6	1	0	0	0	0	7	^	^	^	^	^	^	^	^	^	^	^	^	0	18-21	Seq, TaqMan (13), LightCycler	RNA	FF	N	^	G	^
Sasaki H, et al. Lung Cancer 2006; 54: 103-108.	Japan and USA	98n+t	117	575	^	^	^	^	^	^	^	362	112	213	3	389	42	186	75	378	37	196	80	2	delEex19, L858R	Seq, TaqMan, LightCycler	DNA/RNA	FF	N	^	^	^
Niho S, et al. J Clin Oncol 2006; 24: 64-69.	Japan	100t	4	13	4	0	0	6	0	3	0	11	4	2	0	8	1	5	3	12	3	1	1	1	18,19,21	Seq	DNA	PET	N	R	G	N
Sasaki H, et al. Lung Cancer 2006; 51: 135-136.	Japan	105t	10	21	7	2	^	^	^	^	12	^	^	^	^	^	^	^	^	^	^	^	^	0	G719S, delEx19, L858R	LightCycler	^	^	N	R	G	P
Riely GJ, et al. Clin Cancer Res 2006; 12: 839-844.	USA	106t	34	50	^	^	^	^	^	^	34	31	31	3	3	14	14	20	20	18	18	16	16	0	delEx19, L858R	RFLP, LightCycler	DNA	PET	N	^	G/E	P
Riely GJ, et al. Clin Cancer Res 2006; 12: 839-844.	USA	106n	36	257	^	^	^	^	^	^	^	236	32	21	4	83	12	174	24	199	14	58	22	0	delEx19, L858R	RFLP, LightCycler	DNA	PET	N	^	^	^
Zhang XT, et al. Ann Oncol 2005; 16: 1334-1342.	China	113t	12	30	8	1	4	8	0	9	0	21	11	9	1	16	3	14	9	12	1	18	11	0	18-21	Seq	DNA	PET	N	R	G	P
Cortez-Funes H, et al. Ann Oncol 2005; 16: 1081-1086.	Spain	114t	10	83	6	6	4	34	0	28	5	42	10	41	0	58	3	25	7	63	4	20	6	0	19,21	Seq	DNA	PET	N	R	G	P
Giaccone G, et al. Clin Cancer Res 2006; 12: 6049-6055.	USA, Netherlands	115t	7	29	4	1	1	11	2	10	0	17	5	12	2	13	1	16	6	24	4	5	3	1	18-21	Seq	DNA	PET	N	R	E	N
Pao W, et al. PNAS 2004; 101: 13306-13311.	USA	123t	7	18	6	2	1	1	0	8	0	^	7	^	0	^	3	^	4	^	2	^	5	0	18-24	Seq	DNA	PET	Y	R	G	^
Pao W, et al. PNAS 2004; 101: 13306-13311.	USA	123t	5	17	5	2	0	0	0	10	0	^	5	^	0	^	3	^	2	^	1	^	4	1	18-24	Seq	DNA	PET	Y	R	E	^
Pao W, et al. PNAS 2004; 101: 13306-13311.	USA	123n	11	96	^	^	^	^	^	^	^	73	11	24	0	^	5	^	6	81	4	15	7	0	whole gene	Seq	DNA	FF	Y	^	^	^
Suzuki M, et al. Cancer 2006; 106: 2200-2207.	Japan	124n	38	150	^	^	^	^	^	^	^	79	36	71	2	101	15	49	23	109	14	41	24	0	18-21	Seq	DNA	FF	N	^	^	^
Kimura H, et al. Clin Cancer Res 2006; 12: 3915-3921.	Japan	130t	13	27	7	2	4	4	2	8	0	23	11	4	2	17	6	10	7	^	^	^	^	0	delEx19, L858R	Scorpion	DNA	Serum and PET	Y	R	G	N
Fujimoto N, et al. Cancer Res 2005; 65: 11478-11485.	USA	131t	5	31	3	1	0	4	2	21	0	^	^	^	^	^	^	^	^	^	^	^	^	0	18-21	Seq	DNA	PET	N	^	G	P
Massarelli E, et al. Clin Cancer Res 2007; 13: 2890-2896.	USA	384t	7	71	5	2	0	9	2	53	0	47	7	24	0	30	2	41	5	54	3	17	4	0	18-21	Seq	DNA	PET	N	R	G/E	P
Herbst RS, et al. J Clin Oncol 2005; 23: 2544-2555.	USA	137t+n	2	9	1	2	1	2	0	3	0	6	2	2	0	2	0	7	2	5	0	4	2	0	19,20,21,23	Seq	DNA	PET	N	R	E	P
Endo K, et al. Oncology Reports 2006; 16: 533-541.	Japan	152t	11	22	9	2	1	4	1	5	0	18	11	4	0	13	5	9	6	10	2	12	9	0	18-21	Seq, TaqMan	DNA	PET/FF		R	G	^
Endo K, et al. Oncology Reports 2006; 16: 533-541.	Japan	152n	31	143	^	^	^	^	^	^	^	87	27	56	4	109	12	34	19	95	12	35	17	0	18-21	Seq, TaqMan (13)	DNA	PET/FF	N	R	G	^
Yatabe Y, et al. J Molec Diagn 2006; 8: 335-341.	Japan	161t	12	29	10	1	2	11	0	5	0	^	^	^	^	^	^	^	^	^	^	^	^	0	18-24	Seq	RNA	PET	N	R	G	P
Yatabe Y, et al. J Molec Diagn 2006; 8: 335-341.	Japan	161n	69	195	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	T790M, L858R, delEx19	Fragment analysis and Cycleave	RNA	PET	N	^	^	^
Hirsch Fr, et al. J Clin Oncol 2006; 24: 5034-5042.	USA	194t + n	26	215	^	^	^	^	^	^	^	108	24	107	2	137	11	78	15	185	15	30	11	1	18-24	ARMS, Seq	DNA	PET	N	R	G	P
Taron M, et al. Clin Cancer Res 2005; 11: 5878-5885.	USA, Japan, Spain, China, Germany	195t	17	68	16	6	1	8	0	34	3	47	17	21	0	45	6	23	11	46	3	22	14	1	18,19,21	Seq	DNA	PET	N	R	G	P
Rosell R, et al. Lung Cancer 2005; 50: 25-33.	Japan, Spain	197t	8	34	7	3	1	11	0	10	2	28	8	6	0	23	4	11	4	24	3	10	5	0	18,19,21	Seq	DNA	PET	N	R	G	P
Balak MN, et al. Clin Cancer Res 2006; 12: 6494-6501.	USA	196t	16	16	16	0	0	0	0	0	0	^	^	^	^	5	5	11	11	6	6	10	10	8	18-24	Seq,T790M,L858R,delEx19	DNA	PET, Pleural effusion	N	^	G/E	P/N
Sequist LV, et al. The Oncologist 2007; 12: 90-98.	USA	198t	28	59	^	^	^	^	^	^	59	^	^	^	^	^	^	^	^	^	^	^	^	0	18-24	Seq	DNA	^	Y	^	G/E	P/N
Sequist LV, et al. The Oncologist 2007; 12: 90-98.	USA	198n+t	68	278	^	^	^	^	^	^	59	255	63	23	5	86	21	192	47	198	30	68	34	7	18-24	Seq	DNA	^	Y	^	G/E	P/N
Jackman DM, et al. J Clin Oncol 2007; 25: 760-766.	USA	239t	9	43	3	2	6	15	0	11	6	^	7	^	2	^	3	^	6	^	7	^	2	1	18-24	Seq	DNA	PET	N	R	E	N
Kim KS, et al. Clin Cancer Res 2005; 11: 2244-2251.	Korea	240t	6	27	6	2	0	^	0	^	0	12	5	15	1	^	3	^	3	21	2	6	4	0	18,19,21	Seq	DNA	PET	Y	R	G	P
Sone T, et al. Cancer 2007; 109: 1836-1844.	Japan	277t	17	59	10	6	5	15	2	21	0	44	14	15	3	35	5	24	12	38	7	21	10	0	18,19,21	Seq	DNA	PET	N	R	G	P
Ichihara S, et al. Int J Cancer 2007; 120: 1239-1247.	Japan	280t	38	98	22	3	10	36	4	20	3	82	35	16	3	62	14	36	24	61	^	37	^	3	18-21	Seq	DNA	PET, FF, Pleural effusion	N	WHO	G	P
Soh J, et al. Int J Cancer 2007; 121: 1162-1167.	Japan	383t	28	74	16	3	^	^	^	^	55	60	25	14	3	40	12	24	16	50	10	24	18	2	18-21	Seq	DNA	PET, FF, Pleural effusion	N	WHO	G	P
Soh J, et al. Int J Cancer 2006; 119: 2352-2358.	Japan	283t	10	29	7	0	3	10	0	9	0	26	10	3	0	15	^	14	^	13	^	16	^	0	19, 21	Seq, PNA-LNA PCR clamp	DNA	Pleural effusion	N	WHO	G	P
Soh J, et al. Int J Cancer 2006; 119: 2352-2358.	Japan	283n	6	32	^	^	^	^	^	^	^	27	6	5	0	25	^	7	^	^	^	^	^	0	19, 21	Seq, PNA-LNA PCR clamp	DNA	Pleural effusion	N	WHO	G	P
Ohtsuka K, et al. J Thorac Oncol 2006; 1: 787-795.	Japan	329t	3	9	1	0	2	1	0	5	0	4	1	5	2	5	2	4	1	3	1	6	2	0	18-21	Seq	DNA	FF	Y	R	G	P
Ohtsuka K, et al. J Thorac Oncol 2006; 1: 787-795.	Japan	329n	22	39	^	^	^	^	^	^	^	16	6	23	16	22	9	17	13	21	8	18	14	2	18-21	Seq	DNA	FF	Y	^	^	^
Koyama N, et al. Anticancer Res 2006; 26: 4519-4526.	Japan	331t + n	18	44	15	8	1	6	0	4	0	40	18	4	0	18	8	26	10	15	5	29	13	0	18-21	Seq	DNA	PET	N	^	^	^
Satouchi M, et al. Br J Cancer 2007; 96: 1191-1196.	Japan	333t	28	91	20	7	8	25	0	31	0	81	27	10	1	59	12	32	16	53	11	38	17	0	delEx19, L858R	LightCycler	DNA	PET	N	R	G	P
Sutani A, et al. Br J Cancer 2006; 95: 1483-1489.	Japan	334t + n	38	100	21	0	5	0	1	0	0	76	33	24	5	66	15	34	23	53	13	47	25	0	18,19,21	PNA-LNA PCR Clamp	DNA	Sputum, pleural effusion, Cytology, PET	N	R	G	P
Tsao MS, et al. NEJM 2005; 353: 133-144.	USA, Japan	121t	40	177	^	^	^	^	^	^	^	95	27	82	13	111	24	66	16	124	26	42	14	5	18-21	Seq	DNA	PET	N	R	E	P
Inukai M, et al. Cancer Res 2006; 66: 7854-7858.	Japan	96n+t	101	280	^	^	^	^	^	^	^	205	^	75	^	191	^	89	^	185	^	95	^	6	18-21	Seq, T790M	DNA	PET	Y	^	G	^
Shoji F, et al. Eur J Surg Oncol 2008; 34: 89-93.	Japan	394t	19	32	13	4	^	^	^	^	15	32	19	0	0	12	^	20	^	12	^	20	^	1	18,19,21	Seq	DNA	PET	N	R	G	P
Chin TM, et al. Clin Chem 2007; 53: 62-70.	Singapore	353t	6	10	4	1	^	^	^	^	5	^	^	^	^	3	2	7	4	2	1	7	5	0	18-21	Seq, DHPLC	DNA	PET	Y	R	G	^
Chin TM, et al. Clin Chem 2007; 53: 62-70.	Singapore, Japan, Australia	353n	39	150	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	6	18-21	Seq, DHPLC	DNA	PET/FF	N	^	^	^
Hung MS, et al. Chang Gung Med J; 2006: 373-379.	Taiwan	363t + n	12	29	4	0	1	0	0	6	0	26	11	3	1	14	5	15	7	8	2	21	10	0	18-21	Seq	DNA	Pleural Fluid	N	R	G	P
Zhang GC, et al. Clin Oncol 2007; 19: 499-506.	China	395t	16	25	9	3	4	4	2	2	1	20	12	3	2	15	11	10	5	12	9	13	7	3	18,19,21	Seq	DNA	PET/FF	N	^	G	P
Zhang GC, et al. Clin Oncol 2007; 19: 499-506.	China	395n	13	120	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	2	18,19,21	Seq	DNA	PET/FF	N	^	^	^
Yoshimoto A, et al. Am J Med Sci 2007; 333: 221-225.	Japan	393t	1	1	1	0	0	0	0	0	0	1	1	0	0	1	1	0	0	1	1	0	0	0	18,19,21, T790M	Seq	DNA	PET	N	^	G	P
Brachtel EF, et al. Diagn Cytopathol 2007; 35: 257-262.	USA	390t + n	13	37	^	^	^	^	^	^	4	^	^	^	^	16	5	21	8	24	4	13	9	1	18-24	Seq	DNA	Cytology, PET/FF	Y	^	G/E	^
Buckingham LE, et al. J Thorac Oncol 2007; 2: 414-422.	USA	388t	17	58	^	^	^	^	^	^	58	^	^	^	^	^	^	^	^	^	^	^	^	0	18,19,21	SSCP, Seq	DNA	PET	N	R	G	P
Soh J, et al. Lung Cancer 2007; 56: 445-448.	Japan	389t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	1	1	1	18-21	Seq, RFLP	DNA	Pleural fluid	N	R	G	N
Okano T, et al. Clin Cancer Res 2007; 13: 799-805.	Japan	279t	38	73	31	4	3	7	1	21	6	73	38	0	0	42	22	31	16	38	18	35	20	4	18-24	Seq	DNA	FF	N	R	G	P
Wu YL, et al. J Thorac Oncol 2007; 2: 430-439.	China	387t	57	57	^	^	^	^	^	^	57	^	^	^	^	^	^	^	^	^	^	^	^	0	18-21, (G719C, T790M and 6 others excluded from analysis)	Seq	DNA	PET/FF	N	R	G	^
Wu YL, et al. J Thorac Oncol 2007; 2: 430-439.	China	387n	79	288	^	^	^	^	^	^	^	171	^	117	^	190	^	98	^	155	^	133	^	0	18-21, (G719C, T790M and 6 others excluded from analysis)	Seq	DNA	PET/FF	N	^	^	^
Wu YL, et al. J Thorac Oncol 2007; 2: 430-439.	China	SYSU	10	52	^	^	^	^	^	^	^	28	8	24	2	39	7	13	3	33	4	19	6	0	18-21, (G719C, T790M and 6 others excluded from analysis)	Seq	DNA	PET/FF	N	^	^	^
Wu YL, et al. J Thorac Oncol 2007; 2: 430-439.	China	GDPPH	42	142	^	^	^	^	^	^	30	88	36	54	6	98	26	44	16	84	19	58	23	0	18-21, (G719C, T790M and 6 others excluded from analysis)	Seq	DNA	PET/FF	N	R	G	^
Wu YL, et al. J Thorac Oncol 2007; 2: 430-439.	China	SHPH	21	81	^	^	^	^	^	^	^	38	16	43	5	52	7	29	14	41	5	40	16	0	18-21, (G719C, T790M and 6 others excluded from analysis)	Seq	DNA	PET/FF	N	^	^	^
Wu YL, et al. J Thorac Oncol 2007; 2: 430-439.	China	PKUMCH	31	76	^	^	^	^	^	^	27	51	29	25	2	41	15	35	16	12	1	18	11	0	18-21, (G719C, T790M and 6 others excluded from analysis)	Seq	DNA	PET/FF	N	R	G	^
Wu YL, et al. J Thorac Oncol 2007; 2: 430-439.	China	CHMC	27	101	^	^	^	^	^	^	^	51	24	50	3	72	13	29	14	63	4	38	5	0	18-21, (G719C, T790M and 6 others excluded from analysis)	Seq	DNA	PET/FF	N	^	^	^
Wu YL, et al. J Thorac Oncol 2007; 2: 430-439.	China	JLU	21	54	^	^	^	^	^	^	^	^	^	^	^	27	8	27	13	18	5	36	16	0	18-21, (G719C, T790M and 6 others excluded from analysis)	Seq	DNA	PET/FF	N	^	^	^
Daniele L, et al. Mol Cancer Ther 2007; 6: 1223-1229.	Italy	380t	7	42	7	5	^	^	^	^	30	^	^	^	^	28	^	14	^	^	^	^	^	0	19,21	Seq	DNA	Cytology, PET	N	R	G	P
Choong NW, et al. Nature Clin Pract 2006; 31: 50-57.	Japan, USA	27t	2	2	2	0	0	0	0	0	0	2	2	0	0	0	0	2	2	0	0	2	2	2	Gene	Seq	DNA	PET	Y	R	G/E	P
Matsumoto S, et al. Int J Cancer 2006; 119: 1491-1494.	Japan	32n	12	19	^	^	^	^	^	^	^	19	12	0	0	13	6	6	6	13	6	6	6	0	18-21	Seq	DNA	PET	N	^	^	^
Mukohara T, et al. JNCI 2005; 97: 1185-1194.	USA	33t	4	4	4	0	0	0	0	0	0	3	3	1	1	1	1	3	3	4	4	0	0	0	18-21	Seq	DNA	PET	N	R	G	P
Kobayashi S, et al. NEJM 2005; 352: 786-792.	USA	34t	1	1	1	0	0	0	0	0	0	1	1	0	0	1	1	0	0	1	1	0	0	1	18-21	Seq	DNA	PET	N	R	G	P
Giaccone G, Nat Clin Pract Oncol 2005; 2: 296-297.	USA	79t	1	1	1	0	0	0	0	0	0	1	1	0	0	1	1	0	0	1	1	0	0	1	18-21	Seq	DNA	PET, Cytology	N	R	G	P
Cho D, et al. J Clin Oncol 2005; 23: 235-237.	USA	56t	1	1	1	0	0	0	0	0	0	1	1	0	0	1	1	0	0	1	1	0	0	1	18-24	Seq	DNA	PET	N	R	G	P
Pao W, et al. PLoS Med 2005; 2: e73.	USA	36t	6	6	6	0	0	0	0	0	0	3	3	0	0	0	0	3	3	1	1	2	2	3	18-24	Seq	DNA	PET, Pleural effusion	N	R	G/E	P
Haneda H, et al. Lung Cancer 2006; 52: 47-52.	Japan	42n	37	95	^	^	^	^	^	^	^	95	37	0	0	46	15	49	22	37	11	58	26	1	18-21	TaqMan (13)	DNA	PET/FF	N	^	^	^
Asano H, et al. Clin Cancer Res 2006; 12: 43-48.	Japan	45n	51	146	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	L858R, delEx19	MEP	DNA	PET, Pleural fluid	N	^	^	^
Asano H, et al. Clin Cancer Res 2006; 12: 43-48.	Japan	45n	14	38	^	^	^	^	^	^	^	^	14	^	^	^	^	^	^	^	^	^	^	0	L858R, delEx19	MEP	DNA	PET, Pleural fluid	N	^	^	^
Schwab R, et al. J Clin Oncol 2005; 23: 7736-7738.	Hungary	47t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	1	1	0	18,19,21	Seq	DNA	PET	Y	^	G	P
Soung YH, et al. Virchows Arch 2005; 446: 483-488.	Korea	50n	30	153	^	^	^	^	^	^	^	69	26	84	4	111	13	42	17	99	5	54	25	0	18,19,21	Seq, SSCP	DNA	PET	N	^	^	^
Dragnev KH, et al. J Clin Oncol 2005; 23: 8757-8764.	Lebanon	55t	0	2	0	2	0	0	0	0	0	^	^	^	^	^	^	^	^	^	^	^	^	0	18,19,21	Seq	DNA	PET	N	R	E	P
Shibata M, et al. Clin Cancer Res 2005; 11: 6177-6185.	Japan	64n	26	55	^	^	^	^	^	^	^	55	26	0	0	28	^	27	^	28	^	27	^	0	18,19,21,23	Seq	DNA	PET	N	^	^	^
Yeh KH, et al. Anti Cancer Drugs 2005; 16: 739-742.	Taiwan	65t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	1	1	0	^	^	^	^	N	^	G	P
Pham Dk, et al. J Clin Oncol 2006; 24: 1700-1704.	USA	70n	65	265	^	^	^	^	^	^	^	265	65	0	0	89	24	176	41	198	31	67	34	0	19,21	Seq	DNA	PET	N	^	^	^
Bell DW, et al. Nature Genetics 2005; 37: 1315-1316.	USA	74t	2	2	0	0	1	0	1	0	0	1	1	1	1	2	2	0	0	^	^	^	^	2	18-21	Seq	DNA	PET	Y	R	G	^
Jackman DM, et al. J Clin Oncol 2006; 24: 4517-4520.	USA	75t	1	1	1	0	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	1	1	1	18-21	Seq	DNA	PET	N	R	G	N
Cortese JF, et al. Int J Cancer 2006; 118: 521-522.	USA	76n	19	99	^	^	^	^	^	^	^	99	19	0	0	^	^	^	^	^	^	^	^	0	L858R, delEx19, L861Q, G719C/S, 18,19	Seq, LightCycler	DNA	PET	N	^	^	^
Jiang B, et al. Clin Oncol 2006; 18: 635-639.	China	77n	26	101	^	^	^	^	^	^	^	52	23	49	3	72	12	29	14	66	3	35	23	0	18,19,21	Seq	DNA	^	N	^	^	^
Toyooka S, et al. Cancer Res 2006; 66: 1371-1375.	Japan	84n	74	164	^	^	^	^	^	^	^	164	74	0	0	87	30	77	44	86	22	78	52	0	18-21	Seq	DNA	FF	N	^	^	^
Engelman JA, et al. J Clin Investigation 2006; 116: 2695-2706.	USA	99t	2	2	^	^	^	^	^	^	2	^	^	^	^	^	^	^	^	^	^	^	^	2	Gene	Seq, Surveyor	DNA	PET	N	^	^	^
Engelman JA, et al. J Clin Investigation 2006; 116: 2695-2706.	USA	99n	1	1	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	Gene	Seq, Surveyor	DNA	PET	N	^	^	^
Al-Kuraya K, et al. Human Pathol 2006; 37: 453-457.	Saudia Arabia	2n	1	34	^	^	^	^	^	^	^	20	1	14	0	^	^	^	^	^	1	^	^	0	18-21	Seq	DNA	PET	N	^	^	^
Sugio H, et al. Br J Cancer 2006; 94: 896-903.	Japan	14n	138	469	^	^	^	^	^	^	^	322	136	147	2	302	62	167	76	331	64	138	74	1	delEx19, L858R	MASA	DNA	PET/FF	N	^	^	^
Haneda H, et al. Jpn J Clin Oncol 2006; 36: 69-75.	Japan	15n	52	112	^	^	^	^	^	^	^	112	52	^	^	70	22	42	30	63	19	49	33	0	18-21	Seq/TaqMan	DNA	PET/FF	N	^	^	^
Tam IYS, et al. Clin Cancer Res 2006; 12: 1647-1653.	Hong Kong	22n	115	241	^	^	^	^	^	^	^	215	115	26	0	103	28	138	87	103	21	138	94	14	18-21	Seq	DNA	PET/FF	Y	^	^	^
Kosaka T, et al. Clin Cancer Res 2006; 12: 5764-5769.	Japan	26t	14	14	^	^	^	^	^	^	14	14	14	0	0	4	4	10	10	6	6	8	8	8	18-21, T790M	Seq	DNA/RNA	PET/FF, Pleural fluid	N	^	G	P
Inoue A, et al. J Clin Oncol 2006; 24: 3340-3346.	Japan	30t	16	16	12	^	2	^	2	^	0	16	16	0	0	2	2	14	14	1	1	15	15	0	18-23	Seq	DNA	PET	N	R	G	N
Inoue A, et al. J Clin Oncol 2006; 24: 3340-3346.	Japan	30n	9	59	^	^	^	^	^	^	^	48	8	11	1	28	2	31	7	39	2	20	7	0	18-23	Seq	DNA	PET	N	^	^	^
Sriuranpong V, et al. Cancer Letters 2006; 239: 292-297.	Thailand	31n+t	34	60	3	0	0	0	0	2	0	60	34	0	0	37	18	23	16	23	11	22	18	1	18-21	Seq	DNA	PET	N	^	^	^
Willmore-Payne C, et al. Hum Pathol 2006; 37: 755-763.	USA	37n	6	39	^	^	^	^	^	^	^	39	6	^	^	17	^	21	^	^	^	^	^	1	18-21	Seq, LightCycler	DNA	PET	N	^	^	^
Marchetti A, et al. J Clin Oncol 2005; 23: 857-865.	Italy	44n	39	860	^	^	^	^	^	^	^	375	39	485	0	748	18	112	21	745	16	115	23	0	18,19,21	SSCP, Seq	DNA	FF	Y	^	^	^
Kosaka T, et al. Cancer Res 2004; 64: 8919-8923.	Japan	51n	111	277	^	^	^	^	^	^	^	224	110	53	1	159	41	118	70	162	35	115	76	6	18-21	Seq	RNA	FF	N	^	^	^
Yatabe Y, et al. Am J Surg Pathol 2005; 29: 633-639.	Japan	322n	98	241	^	^	^	^	^	^	^	195	97	46	1	^	^	^	^	^	^	^	^	0	18-21	Seq	RNA	FF	N	^	^	^
Suzuki M, et al. Hum Pathol 2005; 36: 1127-1134.	Japan	58n	37	130	^	^	^	^	^	^	^	76	33	54	4	86	14	44	23	86	13	44	24	0	18-21	Seq	DNA	FF	N	^	^	^
Pan ZK, et al. Chinese J Cancer 2005; 24: 919-923.	China	61n	10	52	^	^	^	^	^	^	^	27	8	25	2	39	7	13	3	35	3	17	7	0	19,21	Seq	DNA	PET	Y	^	^	^
Sonobe M, et al. Br J Cancer 2005; 93: 355-363.	Japan	63n	60	154	^	^	^	^	^	^	^	108	60	46	0	94	18	60	42	98	16	56	44	1	18-21	SSCP, Seq	DNA	FF	Y	^	^	^
Sonobe M, et al. J Mol Diagn 2006; 8: 351-356.	Japan	337n	80	223	^	^	^	^	^	^	^	153	80	70	0	137	22	86	58	144	20	79	60	0	18-21	SSCP, Seq	DNA	FF	Y	^	^	^
Hsieh RK, et al. Chest 2005; 128: 317-321.	Taiwan	66n	17	35	^	^	^	^	^	^	^	35	17	0	0	17	4	18	13	14	3	21	14	0	18,19,21	Seq	DNA	PET	N	^	^	^
Shigematsu H, et al. JNCI 2005; 97: 339-346.	Japan, Taiwan, USA, Australia	91t+n	120	519	^	^	^	^	^	^	^	289	114	230	6	348	48	171	72	353	35	166	85	4	18-24	Seq	DNA	PET	N	^	^	^
Tang X, et al. Cancer Res 2005; 65: 7568-7572.	USA, Japan	67n	21	21	^	^	^	^	^	^	^	20	20	1	1	6	6	15	15	9	9	12	12	3	18-21	Seq	DNA	PET	Y	^	^	^
Yang SH et al. Clin Cancer Res 2005; 11: 2106-2110.	USA, Italy	92n	26	219	^	^	^	^	^	^	^	164	25	55	1	134	12	85	14	185	14	34	12	1	18-21	Seq	DNA	FF	Y	^	^	^
Kondo M, et al. Lung Cancer 2005; 50: 385-391.	Japan	60t	4	12	4	0	0	^	0	^	8	9	4	3	0	6	2	6	2	6	1	6	3	0	18,19,21	Seq	DNA	PET	Y	^	G	N
Kondo M, et al. Lung Cancer 2005; 50: 385-391.	Japan	60n	9	73	^	^	^	^	^	^	^	53	13	20	0	47	4	26	9	48	6	25	7	0	18,19,21	Seq	DNA	PET	Y	^	^	^
Yokoyama T, et al. Cancer Science 2006; 97: 753-759.	Japan	94n	98	337	^	^	^	^	^	^	^	233	97	104	1	220	33	117	65	219	28	101	68	7	18-21	Seq, SSCP	DNA	FF	Y	^	^	^
Yokoyama T, et al. Cancer Science 2006; 97: 753-759.	Japan	94t	4	12	4	^	0	^	0	^	8	9	4	3	0	6	2	6	2	6	1	6	3	0	18,19,21	Seq	DNA	PET	Y	^	G	N
Sequist LV, et al. Clin Cancer Res 2006; 12: 4403s-4408s.	USA, other	68n	23	94	^	^	^	^	^	^	^	^	^	^	^	31	^	63	^	65	^	29	^	2	18-24	Seq	DNA	PET/FF	Y	^	^	^
Sueoka N, et al. J Cancer Res Clin Oncol 2007; 133: 93-102.	Japan	101t	7	7	^	^	^	^	^	^	7	7	7	0	0	2	2	5	5	3	3	4	4	0	18,19,21	DHPLC, Seq	DNA	FF, Pleural effusion	N	^	G	^
Sueoka N, et al. J Cancer Res Clin Oncol 2007; 133: 93-102.	Japan	101n	27	90	^	^	^	^	^	^	^	69	26	21	1	57	8	33	19	54	7	36	20	0	18,19,21	DHPLC, Seq	DNA	FF, Pleural effusion	N	^	^	^
Cappuzzo F, et al. J Clin Oncol 2005; 23: 5007-5018.	USA	104t	15	89	8	3	1	20	6	50	1	^	^	^	^	^	^	^	^	^	^	^	^	0	18-21	Seq	DNA, RNA	PET	N	R	G	P
Asahina H, et al. Br J Cancer 2006; 95: 998-1004.	Japan	122t	16	16	12	0	1	0	3	0	0	15	15	1	1	3	3	13	13	2	2	14	14	0	18-21	Seq	DNA	PET	N	R	G	N
Asahina H, et al. Br J Cancer 2006; 95: 998-1004.	Japan	122n	4	66	^	^	^	^	^	^	^	57	4	9	0	30	2	36	2	42	3	24	1	0	18-21	Seq	DNA	PET	N	^	^	^
Blons H, et al. Am J Surg Pathol 2006; 30: 1309-1315.	France	140n	13	91	^	^	^	^	^	^	^	63	12	28	1	46	1	45	12	69	1	21	12	1	18-21	Seq, RFLP	DNA	PET/FF	Y	^	^	^
Murray S, et al. Lung Cancer 2006; 52: 225-233.	Greece, Czech Republic	158n	9	51	^	^	^	^	^	^	^	15	3	45	6	51	6	9	3	45	5	13	4	3	18-21	Seq, RFLP	DNA	PET	Y	^	^	^	Yes (01/11/07)
Conde E, et al. Clin Cancer Res 2006; 12: 710-717.	Spain	232n	11	86	^	^	^	^	^	^	^	47	7	39	4	56	4	30	7	61	2	17	7	0	18-21	Seq	DNA	PET/FF	Y	^	^	^
Na II, et al. Lung Cancer 2007; 57: 96-102.	Korea	266n	24	97	^	^	^	^	^	^	^	76	21	21	3	40	7	57	17	43	6	54	18	0	18-21	Seq	DNA	PET	N	^	^	^
Sonobe M, et al. J Surg Oncol 2007; 95: 63-69.	Japan	268n	17	53	^	^	^	^	^	^	^	39	16	14	1	36	^	17	^	39	^	14	^	0	18-21	SSCP, Seq	DNA	FF	N	^	^	^
Kang SM, et al. Cancer 2007; 109: 581-587.	Korea	269n	11	25	^	^	^	^	^	^	^	25	11	0	0	15	3	10	8	12	3	13	8	0	18-21	Seq	DNA	PET	N	^	^	^
Sunaga N, et al. Lung Cancer 2007; 56: 383-389.	Japan	274t	21	21	16	0	3	0	0	0	2	21	21	0	0	4	4	17	17	2	2	19	19	0	19,21	Seq	DNA	PET	N	R	G	P
Sunaga N, et al. Lung Cancer 2007; 56: 383-389.	Japan	274n	0	12	^	^	^	^	^	^	^	12	0	0	0	5	0	7	0	6	0	6	0	0	19,21	Seq	DNA	PET	N	^	^	^
Tsao AS, et al. J Thorac Oncol 2006; 1: 231-239.	USA	332n	14	159	^	^	^	^	^	^	^	82	14	63	0	85	3	74	11	136	6	23	8	0	18-21	Seq	DNA	PET/FF	N	^	^	^
Tsao AS, et al. J Thorac Oncol 2006; 1: 231-239.	USA	332n	10	22	^	^	^	^	^	^	^	^	^	^	^	11	6	11	6	13	7	9	5	0	18-21	Seq	DNA	PET/FF	N	^	^	^
Gow CH, et al. PLoS Med 2005; 2: e269.	Taiwan	243t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	1	1	1	18-21	Seq	DNA	PET	Y	^	G	N
Shih JY, et al. NEJM 2005; 353: 207-208.	Taiwan	257t	1	1	0	0	0	0	1	0	0	1	1	0	0	0	0	1	1	0	0	1	1	1	18-21	Seq	DNA	PET	N	^	G	N
Tsuchihashi Z, et al. NEJM 2005; 353: 208-209.	USA	258n	3	38	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	18,19,21	Seq	^	^	N	^	^	^
Ohtsuka K, et al. Cancer 2007; 109: 741-750.	Japan	267t	1	5	0	0	0	0	0	3	2	0	0	5	1	5	1	0	0	5	1	0	0	0	18-21	Seq	DNA	PET	N	^	G	P
Ohtsuka K, et al. Cancer 2007; 109: 741-750.	Japan	267n	2	37	^	^	^	^	^	^	^	4	2	33	0	33	1	4	1	33	1	4	1	1	18-21	Seq	DNA	PET	N	^	^	^
Cohen V, et al. Cancer 2006; 107: 2858-2865.	Canada	273n	23	104	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	L858R, delEx19	Seq, DHPLC	DNA	PET	N	^	^	^
Nakatomi K, et al. Lung Cancer 2006; 52: 253-255.	Japan	275t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	1	1	0	19,21	Seq, RFLP	DNA	PET	N	^	G	P
Yoshimura N, et al. Lung Cancer 2006; 51: 363-368.	Japan	276t	2	2	1	0	1	0	0	0	0	2	2	0	0	1	1	1	1	1	1	1	1	0	18,19,21	Seq	DNA	PET	N	R	G	P
Uramoto H, et al. Int J Clin Oncol 2006; 11: 487-491.	Japan	281t	1	1	1	0	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	1	1	1	18-23	Seq	DNA	PET, Pleural effusion	N	^	G	p
Asahina H, et al. Lung Cancer 2006; 54: 419-422.	Japan	282t	1	1	0	0	0	0	1	0	0	1	1	0	0	1	1	0	0	1	1	0	0	1	18-21	Seq	DNA	PET	N	R	G	N
Matsukuma S, et al. J Mol Diagn 2006; 8: 504-512.	Japan	102n	35	118	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	delEx19, L858R	LH-MSA	DNA	PET	N	^	^	^
Pao W et al. PLoS Med 2005; 2: e13	USA	111t	8	36	8	2	0	^	0	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	18-21	Seq, RFLP	DNA	PET/FF	N	R	E	^
Pao W et al. PLoS Med 2005; 2: e13	USA	111t	9	24	9	3	0	^	0	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	18-21	Seq, RFLP	DNA	PET/FF	N	R	G	^
Hashimoto N, et al. Lung Cancer 2006; 53: 387-390.	Japan	112t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	1	0	0	1	18-21	Seq	DNA	PET	N	^	G	N
Fujita S, et al. Int J Cancer 2006; 119: 1751-1752.	Japan	128n	4	6	^	^	^	^	^	^	^	6	4	0	0	3	1	3	3	4	2	2	2	0	18,19,21	Seq	DNA	PET/FF	N	^	^	^
Tokumo M, et al. Lung Cancer 2006; 53: 117-121.	Japan	129t	2	2	0	0	0	0	2	0	0	2	2	0	0	0	0	2	2	2	2	0	0	1	18-21	Seq	DNA	PET, Pleural effusion	Y	WHO	G	P
Lange T, et al. Oncology Reports 2005; 14: 1539-1542.	Germany	136t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	1	1	0	18,19,21	Seq	DNA	PET	N	R	G	N
Kobayashi S, et al. Anticancer Res 2006; 26: 1621-1626.	Japan	141t	2	2	2	0	0	0	0	0	0	2	2	0	0	2	2	0	0	2	2	0	0	0	18-21	Seq	DNA	PET	N	^	G	P
Ohnishi H, et al. Diagn Mol Pathol 2006; 15: 101-108.	Japan	143n	23	62	^	^	^	^	^	^	^	54	21	8	2	^	^	^	^	^	^	^	^	3	19, 21	Seq	DNA	PET	N	^	^	^
Leone A, et al. Suppl Tumori 2005; 4: s203.	Argentina	153n	11	150	^	^	^	^	^	^	^	110	11	40	0	^	^	^	^	^	^	^	^	0	19,21	Seq	DNA	PET	N	^	^	^
Zhou C, et al. Cancer 2006; 12: 33-39.	China	200n	21	80	^	^	^	^	^	^	^	38	16	42	5	51	7	29	14	40	4	40	17	0	L858R, delEx19, G719S	TaqMan	DNA	FF	N	^	^	^
Bekaii-Saab T, et al. BMC Cancer 2006; 6: 278	USA	228n	2	44	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	18-21	Seq	DNA	PET	Y	^	^	^
Chou WC, et al. Jpn J Clin Oncol 2006; 36: 523-526.	Taiwan	229t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	1	1	0	18-21	Seq	DNA	PET	N	R	G	P
Takeuchi T, et al. J Clin Oncol 2006; 24: 1679-1688.	Japan	233n	34	149	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	15-24	Seq	RNA	FF	N	^	^	^
Krypuy M, et al. BMC Cancer 2006; 6: 295.	Australia	236n	3	22	^	^	^	^	^	^	^	22	3	0	0	^	^	^	^	^	^	^	^	0	18-21	Seq	DNA	^	N	^	^	^
Milton DT, et al. J Clin Oncol 2006; 24: 4940-4942.	USA	302t	1	1	1	0	0	0	0	0	0	1	1	0	0	1	1	0	0	1	1	0	0	1	18-21	Seq	DNA	PET	N	R	G	P
Matsuo K, et al. Cancer Sci 2007; 98: 96-101.	Japan	319n	152	435	^	^	^	^	^	^	^	347	147	88	5	262	57	173	95	268	48	167	104	0	delEx19, L858R in 167; rest 18-24	Seq	DNA/RNA	PET/FF	N	^	^	^
Gallegos Ruiz MI, et al. J Thorac Oncol 2007; 2: 12-21.	Netherlands	320t	1	2	1	0	0	0	0	1	0	2	1	0	0	1	1	1	0	2	1	0	0	0	18-21	Seq	DNA	PET	N	R	G	P
Suzuki S, et al. Modern Pathology 2006; 19: 986-998.	Japan	321n	5	28	^	^	^	^	^	^	^	17	5	11	0	^	^	^	^	^	^	^	^	0	18-21	Seq	DNA	FF	Y	^	^	^
Lai RS, et al. Chin J Oncol 2006; 28: 599-602.	China	324n	6	32	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	1	18,19,21	Seq	DNA	^	N	^	^	^
Chantranuwat C, et al. J Med Assoc Thai 2005; 88: s322-329.	Thailand	326n	33	58	^	^	^	^	^	^	^	58	33	0	0	38	20	20	13	^	^	^	^	0	19,21	Seq	DNA	PET	N	^	^	^
Imai H, et al. Nihon Kokyuki Gakkai Zasshi 2007; 45: 189-193.	China	327t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	^	^	^	^	0	^	^	^	^	N	^	G	^
Liu F, et al. Chin J Med Genet 2007; 24: 31-34.	China	328n+t	26	101	^	^	^	^	^	^	10	67	26	34	0	72	12	29	14	66	3	35	23	0	18,19,21	Seq	^	^	^	^	^	^
Xu CR, et al. Natl Med J China 2006; 86: 2606-2610.	China	330n+t	29	135	^	^	^	^	^	^	20	^	^	^	^	94	18	41	11	54	^	81	^	3	18,19,21	Seq	DNA	PET	^	^	G	^
Ryoo BY, et al. Lung Cancer 2006; 53: 245-248.	Korea	284t	1	1	0	0	1	0	0	0	0	0	0	1	1	1	1	0	0	1	1	0	0	0	18-21	Seq	DNA	^	N	^	G	P
Sasaki H, et al. Lung Cancer 2007; 55: 129-130.	Japan	285n	4	26	^	^	^	^	^	^	^	0	0	26	4	21	1	5	3	20	1	6	3	0	^	^	^	^	N	^	^	^
Takahashi K, et al. Clin Cancer Res 2007; 13: 111-120.	Japan	286n	0	2	^	^	^	^	^	^	^	0	0	2	0	2	0	0	0	2	0	0	0	0	18-21	Seq	DNA	PET/FF, Autopsy	Y	^	^	^
Huang MJ, et al. Lung Cancer 2005; 49: 413-415.	Taiwan	287t	1	1	1	0	0	0	0	0	0	1	1	0	0	1	1	0	0	1	1	0	0	0	18,19,21	Seq	DNA	Pleural effusion	N	^	G	N
Yoshida Y, et al. Lung Cancer 2005; 50: 1-8.	Japan	290n	18	51	^	^	^	^	^	^	^	^	17	^	1	20	5	49	13	18	5	51	13	0	18,19,21	Seq	DNA	PET	N	^	^	^
Chang YL, et al. Clin Cancer Res 2007; 13: 52-58.	Taiwan	292n	44	58	^	^	^	^	^	^	^	54	42	4	2	35	25	23	19	17	14	41	30	0	18-22	Seq	DNA	PET	Y	^	^	^
Buttitta F, et al. Int J Cancer 2006; 119: 2586-2591.	Italy	293n	43	403	^	^	^	^	^	^	^	403	43	0	0	329	^	74	^	307	^	96	^	0	18-22	Seq, SSCP	DNA	FF	Y	^	^	^
Sasaki H, et al. J Surgical Res 2006; 133: 203-206.	Japan	344n	43	129	^	^	^	^	^	^	^	97	42	21	1	91	17	38	26	83	14	46	29	0	^	Seq	RNA	FF	Y	^	^	^
Soung YH, et al. Oncology 2006; 70: 285-289.	Korea	346n	1	2	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	^	SSCP, Seq	DNA	Methacarn	N	^	^	^
Tanaka T, et al. Cancer Sci 2007; 98: 246-252.	Japan	348n	45	132	^	^	^	^	^	^	^	102	43	30	2	80	19	52	26	^	^	^	^	0	G719C/S, L858R, L861Q, delEx19	PNA-LNA PCR	DNA	Cytology, PET	N	^	^	^
Bae NC, et al. Cancer Genetics and Cytogenetics 2007; 173: 107-113.	Korea	352n	20	115	^	^	^	^	^	^	^	55	20	60	0	87	7	28	13	92	7	23	13	0	18-21	Seq	DNA	FF	Y	^	^	^
Franco-Hernandez C, et al. Cancer Genetics and Cytogenetics 2007; 173: 63-67.	Spain	356n	1	6	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	18-26	Seq	DNA	FF	Y	^	^	^
Seki N, et al. J Clin Oncol 2006; 24: 3213-3214.	Japan	357t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	1	1	0	^	^	^	^	N	^	G	P
Dong QG, et al. Chin J Oncol 2006; 28: 686-690.	China	373n	57	176	^	^	^	^	^	^	^	^	^	^	^	130	35	46	22	^	^	^	^	0	^	^	^	^	N	^	^	^
Achille M, et al. Clin Lung Cancer 2006; 8: 214-216.	USA	374t	1	1	0	1	0	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	0	0	18,20,21	Seq	DNA	PET	N	^	E	N
Eberhard DA, et al. J Clin Oncol 2005; 23: 5900-5909.	USA	48n	29	228	^	^	^	^	^	^	^	120	20	99	9	128	16	100	13	208	24	20	5	2	18-21	Seq	DNA	PET	N	R	E+C	N
Qin BM, et al. Cell Res 2005; 15: 212-217.	China	53n	10	41	^	^	^	^	^	^	^	17	7	24	3	30	6	11	4	20	4	21	6	1	18-21	Seq	RNA	FF	Y	^	^	^
Horiike A, et al. Chest 2007; 131: 1628-1634.	Japan	385n+t	31	91	1	1	0	0	0	0	0	^	23	^	8	^	17	^	14	^	17	^	14	0	19,21, L858R, delEx19	Seq, Scorpion ARMS	DNA	Aspiration and Biopsies	N	^	^	^
Engelman JA, et al. Science 2007; 316: 1039-1043.	USA, China, Italy, Japan	386n	18	18	0	0	0	0	0	0	18	^	^	^	^	^	^	^	^	^	^	^	^	2	18-21	Seq, Surveyor, T790M, Cycleave	^	^	N	^	G/E	^
Fischer JR, et al. Pneumologie 2007; 61: 264-269.	Germany	401t	9	10	^	^	^	^	^	^	10	8	8	2	1	4	3	6	6	^	^	^	^	1	18-21	Seq	DNA	PET	N	^	G	P
Nomura M, et al. PLoS Med 2007; 4: e125.	USA, Australia, Japan, Taiwan	377n	126	556	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	18-21	Seq, RFLP L858R and delEx19	DNA	PET/FF	Y	^	^	^
Pan Q, et al. J Mol Diagn 2005; 7: 396-403.	USA	135n	29	39	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	^	0	19,21	delEx19, L858R RFLP	DNA	^	N	^	^	^
Jackman DM, et al. Clin Cancer Res 2006; 12: 3908-3914.	USA	144t	36	36	21	0	6	0	0	0	4	29	29	3	3	12	12	20	20	17	17	15	15	0	18-24	Seq, Surveyor 18-21	DNA	PET/FF	N	R	G/E	P
Liu Y, et al. BMC Cancer 2007; 7: 74.	USA	379n	10	70	^	^	^	^	^	^	^	^	^	^	^	^	1	^	9	30	0	40	10	0	18-21	Seq	DNA	PET	Y	^	^	^
Marks JL, et al. PLoS ONE 2007; 5: e426.	USA	378n	13	261	^	^	^	^	^	^	^	^	13	^	0	^	6	^	7	^	9	^	4	0	18-24	Seq	DNA	FF	Y	^	^	^
Soung TH, et al. Int J Cancer 2006; 118: 1426-1429.	Korea	9n	0	5	^	^	^	^	^	^	^	2	0	3	0	5	0	0	0	^	^	^	^	0	18-21	SSCP-Seq	DNA	Methacarn	Y	^	^	^
Ma ESK, et al. Int J Cancer 2007; 120: 1828-1831.	Hong Kong	402t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	18-21	Seq	DNA	PET	Y	R	G	N
Ikeda S, et al. Pathology International 207; 57: 594-599.	Japan	404n	12	26	^	^	^	^	^	^	^	26	12	0	0	11	4	15	8	12	4	14	8	0	L858R	ARMS, Seq, RFLP	DNA	PET	N	^	^	^
Zhang W, et al. J Thorac Oncol 2006; 1: 635-647.	USA	403n	14	90	^	^	^	^	^	^	^	^	^	^	^	18	1	72	13	46	2	44	12	2	18-21	Seq	DNA	PET	Y	^	^	^
Shibata T, et al. Cancer Sci 2007; 98: 985-991.	Japan	405n	36	86	^	^	^	^	^	^	^	86	36	0	0	49	16	37	20	45	15	41	21	0	18-21	Seq	DNA	FF	N	^	^	^
Argiris A, et al. J Thorac Oncol 2006; 1: 52-60.	USA	406t	3	35	1	^	2	^	^	^	32		^	^	^	^	1	^	2	^	1	^	2	0	18,19,21	Seq (Ex19), Pyrosequencing G719X, L858R, L861Q	DNA	PET	N	R	G	P
Endoh H, et al. J Thorac Oncol 2006; 1: 629-634.	Japan	407t	44	78	22	2	3	6	2	17	0	68	43	10	1	44	21	34	23	45	21	33	23	3	18-21	Seq	RNA	FF	N	R	G	N
Yoshida K, et al. J Thorac Oncol 2007; 2: 22-28.	Japan	408n	6	45	^	^	^	^	^	^	^	38	6	7	0	28	2	17	4	34	2	11	7	0	L858R, delEx19	Fragment analysis and Cycleave	DNA	PET/FF	N	^	^	^
Yoshida K, et al. J Thorac Oncol 2007; 2: 22-28.	Japan	408t	21	21	19	0	1	0	1	0	0	21	21	0	0	8	8	13	13	8	8	13	13	0	L858R, delEx19	Fragment analysis and Cycleave	DNA	PET/FF	N	R	G	P
Kimura H, et al. J Thorac Oncol 2006; 1: 260-267.	Japan	409t	4	12	2	^	1	^	1	8	12	^	3	^	1	^	3	^	1	^	^	^	^	0	18,19,21	Seq	DNA	PET	N	R	G	N
Lim EH, et al. J Thoracic Oncol 2007; 2: 387-396.	Singapore	410n	14	60	^	^	^	^	^	^	^	23	7	37	7	47	8	13	6	47	6	13	8	7	18-21	Seq	DNA	FF	N	^	^	^
Dziadziuszko R, et al. J Thorac Oncol 2007; 2: 91-92.	USA	411t	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	1	1	0	^	Seq	^	^	N	^	G	P
Yano M, et al. J Thorac Oncol 2006; 1: 413-416.	Japan	412n	38	80	^	^	^	^	^	^	^	80	38	0	0	35	10	45	28	33	7	47	31	0	18-21	Seq, TaqMan (13)	DNA	PET/FF	N	^	^	^